Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
The Ted Rogers Centre for Heart Research is thrilled to welcome Dr. Cedric Manlhiot as the inaugural Rogers Innovator of Cardiovascular Precision Medicine at SickKids. In addition to his role at TRCHR, Dr. Manlhiot will be a Scientist in the Translational Medicine...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
Launching in March 2024, emergency department (ED) physicians at the University Health Network (UHN) can now access the Emergency Heart Failure Mortality Risk Grade (EHMRG) calculator within Epic, UHN’s electronic medical record. The EHMRG score estimates the risk of...
Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
Please join us for an ECHO webinar on Tuesday June 15, 2021 (11 am – 12 pm EST) featuring Dr. Gavin Oudit (Founder & Chief Operating Officer, PEARKO Therapeutics Inc.; Professor, Department of Medicine, University of Alberta; Clinician-Scientist, Mazankowski Alberta Heart Institute; Director, Heart Function Clinic; Canada Research Chair in Heart Failure).
Dr. Oudit’s presentation entitled, “Apelin Analogs as Novel Biologics for Cardiovascular Disease”, will feature an overview of PEARKO Therapeutics, its technologies and the story behind its success. PEARKO Therapeutics is a biopharmaceutical company engaged in the practice of translational medicine: catalyzing and driving the translation of molecular discoveries to patients. PEARKO Therapeutics has established itself in the field of cardiovascular medicine with its highly effective and highly versatile biologic: apelin analog therapy.
Register in advance for this meeting: https://us02web.zoom.us/meeting/register/tZcqc-GqqjIiH9XHnsx3G6KM0FXUTbmBcfTH
After registering, you will receive a confirmation email containing information about joining the webinar.
ECHO is an entrepreneurship training program, funded and organized in a partnership between (i) the Translational Biology and Engineering Program (TBEP), the University of Toronto component of the Ted Rogers Centre for Heart Research, and (ii) the Health Innovation Hub (H2i).
